EditCo Bio, Inc. Expands Primary Cell Portfolio with Launch of Knockout CD8+ T-cell Pools
June 27 2024 - 8:01AM
Business Wire
Enhancing Immunotherapy and Cancer Research with Advanced
CRISPR-Mediated Gene Editing
EditCo Bio, Inc., a leader in genome engineering innovation,
announced the expansion of its T-cell editing portfolio with the
launch of Knockout CD8+ T-cell Pools. This new addition builds upon
the success of their Knockout CD4+ T-cell Pools, offering
researchers an advanced tool for primary T-cell editing that brings
unprecedented precision and scalability to cancer and immunotherapy
research.
Leveraging EditCo Bio’s cutting-edge automated platform, the new
Knockout CD8+ T-cell Pools allow researchers to bypass challenging
optimization steps and access highly functional edited T-cells
ready for immediate use. This innovation accelerates the transition
from research discovery to clinical application and delivers
several key benefits:
- Accelerated results: EditCo Bio’s unique 7-day protocol
and proprietary guide RNA technology achieve knockout efficiencies
approaching 100% in primary human CD8+ T-cells. Additionally,
EditCo has several prescreened and optimized donor cells available
to kick off projects immediately.
- Dependable performance: Edited CD8+ T-cell pools
demonstrate exceptional editing efficiency (~100%) and viability
(>85%). with editing efficiency unchanged for at least 4 weeks
in culture.
- Enhanced functionality: Edited CD8+ T-cell pools showed
antigen-specific CD107a mobilization, a hallmark of cytotoxic
activity.
- Customizable solutions: EditCo Bio can efficiently
onboard customer-supplied donor cells, ensuring high knockout
efficiencies, viability, and turn-around times tailored to specific
project needs.
“For researchers working on the front lines of immunotherapy,
having access to high-quality CD8+ T-cells can significantly
accelerate the pace of discovery and therapeutic development," said
Travis Maures, CSO of EditCo Bio. "Our new Knockout CD8+ T-cell
Pools provide the precision, efficiency, and scalability needed to
push the boundaries of what's possible in cellular research.”
The addition of Knockout CD8+ T-cell Pools further strengthens
EditCo Bio’s comprehensive Engineered Cell portfolio, solidifying
its position as a leader in cell engineering solutions. The company
plans to continue to expand its range of edited primary cell
products to include other primary cell subsets, which will be
available later this year.
For more information regarding EditCo Bio’s Knockout T-cell
Pools, visit www.EditCo.bio/contact.
About EditCo Bio, Inc.
EditCo Bio is a pioneer in the development of CRISPR-engineered
cells and high-throughput gene editing solutions. Originally a
spinout of Synthego, EditCo Bio leverages the expertise,
technology, and partnerships that are critical for creating a
novel, end-to-end CRISPR platform able to accelerate scientific
discoveries. They’re dedicated to building out a more accessible
research toolkit to make genome engineering easier, faster, and
more reliable.
To learn more about EditCo Bio, visit our website at
www.EditCo.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627155566/en/
John Latimer pr@editco.bio